Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $610,504 | $311,097 | $229,361 | $365,656 |
| - Cash | $2,867 | $14,691 | $4,999 | $8,740 |
| + Debt | $1,011 | $1,083 | $1,153 | $1,122 |
| Enterprise Value | $608,648 | $297,489 | $225,515 | $358,038 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$10,129 | -$10,231 | -$9,900 | -$8,085 |
| % Margin | – | – | – | – |
| Net Income | -$10,157 | -$7,998 | $15,193 | -$12,113 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.12 | -0.1 | -0.13 | -0.18 |
| % Growth | -20% | 23.1% | 27.8% | – |
| Operating Cash Flow | -$9,566 | -$5,777 | -$8,263 | -$8,465 |
| Capital Expenditures | $0 | -$113 | -$36 | $0 |
| Free Cash Flow | -$9,566 | -$5,890 | -$8,299 | -$8,465 |